Spots Global Cancer Trial Database for esophageal adenocarcinoma
Every month we try and update this database with for esophageal adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Survey Study on Barrett's Esophagus Screening | NCT04408105 | Gastroesophagea... Barrett's Esoph... Esophagus Adeno... | Primary Care Pr... Gastroenterolog... Patient Survey | 18 Years - 99 Years | University of Colorado, Denver | |
| Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer Cachexia | NCT05954117 | Esophageal Aden... | Adipose tissue ... | 18 Years - 99 Years | University Hospital, Clermont-Ferrand | |
| CAlorie and Protein REstriction PROgram in Barrett's Esophagus Patients (CARE-PRO). | NCT03813381 | Barrett's Esoph... Overweight and ... | Calorie and pro... | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Early Detection of Cancer Onset Based on Sensing Field Cancerization at the Organ Level in the Alimentary Tract Using an Integrated Stimulated Raman/Scattering Modality for Endoscopic Real-time in Vivo Measurements | NCT05247346 | Esophageal Aden... Barrett Esophag... Colorectal Aden... Colorectal Poly... Colorectal Neop... Colorectal Aden... Carcinogenesis | SENSITIVE syste... | 18 Years - | University Medical Center Groningen | |
| A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | NCT05563766 | Esophageal Aden... Esophageal Squa... Gastroesophagea... | Itraconazole | 18 Years - | VA Office of Research and Development | |
| Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples | NCT06071845 | Barrett Esophag... Barretts Esopha... Barrett's Esoph... Esophageal Aden... | Cytosponge Proc... Endoscopic Asse... | 18 Years - 90 Years | Mayo Clinic | |
| A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS) for Surveillance of Barrett's Esophagus, the WATS-EURO2 Study | NCT05642338 | Barrett Esophag... Esophageal Aden... Diagnosis | WATS3D | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma | NCT04150640 | Esophageal Aden... Gastric Adenoca... | Nal-IRI Oxaliplatin 5-FU Trastuzumab Pembrolizumab Nivolumab | 18 Years - | University of Wisconsin, Madison | |
| TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer | NCT05188313 | Esophageal Canc... Esophageal Aden... | Trastuzumab Pertuzumab Paclitaxel Carboplatin | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer | NCT00113581 | Esophageal Canc... Gastric Cancer | EMD 72000 (matu... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas | NCT05745857 | Barrett's Esoph... Barrett Oesopha... Esophageal Aden... | Avastin Erbitux Fluorescence en... | 18 Years - | University Medical Center Groningen | |
| Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE | NCT04293458 | Barrett Esophag... Esophageal Aden... Barretts Esopha... Barrett's Esoph... | EsoGuard | 50 Years - | PAVmed Inc. | |
| Evaluation of MicroRNA Expression in Blood and Cytology for Detecting Barrett's Esophagus and Associated Neoplasia | NCT02464930 | Barrett's Esoph... Gastroesophagea... Esophageal Aden... | 18 Years - | Midwest Veterans' Biomedical Research Foundation | ||
| Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma | NCT04150640 | Esophageal Aden... Gastric Adenoca... | Nal-IRI Oxaliplatin 5-FU Trastuzumab Pembrolizumab Nivolumab | 18 Years - | University of Wisconsin, Madison | |
| Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma | NCT00667420 | Esophageal Aden... Gastric Adenoca... | panitumumab, ep... | 18 Years - | Massachusetts General Hospital | |
| RAPA-201 Therapy of Solid Tumors | NCT05144698 | Solid Tumor Breast Cancer Small Cell and ... Triple Negative... Gastric Cancer Esophageal Aden... Gastric Junctio... Esophageal Squa... Head and Neck C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Carcinoma of Un... Bladder Cancer Malignant Melan... | RAPA-201 Rapamy... Chemotherapy Pr... | 18 Years - | Rapa Therapeutics LLC | |
| Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer | NCT00113581 | Esophageal Canc... Gastric Cancer | EMD 72000 (matu... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | NCT05411133 | Gastrointestina... Cholangiocarcin... Liver Cancer Colorectal Aden... Pancreatic Canc... Gastric Cancer Esophageal Aden... Gastroesophagea... | Cabotamig (ARB2... | 18 Years - | Arbele Limited | |
| A Study of KK2269 in Adult Participants With Solid Tumors | NCT06266299 | Advanced Solid ... Metastatic Soli... Gastric Adenoca... Gastroesophagea... Esophageal Aden... Non Small Cell ... | KK2269 Docetaxel | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma | NCT00964080 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | MBP-426/Leucovo... | 18 Years - | Mebiopharm Co., Ltd | |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | NCT05394740 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | Regorafenib Nivolumab CapeOX FOLFOX regimen | 20 Years - | National Cancer Center Hospital East | |
| Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer | NCT03474341 | Esophageal Canc... Esophageal Aden... Esophageal Squa... Esophageal Neop... | MRI PET-CT Endoscopy Blood samples | 18 Years - | UMC Utrecht | |
| A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | NCT05977322 | Pancreatic Duct... Gastroesophagea... Glioblastoma Mu... | 68Ga-FF58 177Lu-FF58 | 18 Years - | Novartis | |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | NCT05394740 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | Regorafenib Nivolumab CapeOX FOLFOX regimen | 20 Years - | National Cancer Center Hospital East | |
| Esophageal Cytology With FISH in Detecting Esophageal Cancer | NCT02100189 | Dysphagia Dysplasia Esophageal Aden... Esophageal Squa... Esophagitis Gastroesophagea... High Grade Dysp... Weight Loss | Cytology Specim... Esophagogastrod... Laboratory Biom... | 18 Years - | OHSU Knight Cancer Institute | |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | NCT04114136 | Melanoma NSCLC Hepatocellular ... Urothelial Canc... Gastric Adenoca... HNSCC Esophageal Aden... Microsatellite ... | Nivolumab or Pe... Metformin Rosiglitazone | 18 Years - | University of Pittsburgh | |
| Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management | NCT02075905 | Barrett's Esoph... Esophageal Aden... Intestinal Meta... Dysplasia | 18 Years - 80 Years | University of North Carolina, Chapel Hill | ||
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | NCT06324357 | Metastatic Brea... Metastatic Gast... Gastroesophagea... Esophageal Aden... | Zongertinib Trastuzumab der... Trastuzumab emt... | 18 Years - | Boehringer Ingelheim | |
| Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors | NCT03982173 | Metastatic Colo... Triple Negative... Prostate Adenoc... Stomach Adenoca... Esophageal Aden... | Tremelimumab Durvalumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery | NCT05713838 | Esophagus Adeno... | Durvalumab FLOT mFOLFOX-6 Radiotherapy | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer | NCT03474341 | Esophageal Canc... Esophageal Aden... Esophageal Squa... Esophageal Neop... | MRI PET-CT Endoscopy Blood samples | 18 Years - | UMC Utrecht | |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | NCT04114136 | Melanoma NSCLC Hepatocellular ... Urothelial Canc... Gastric Adenoca... HNSCC Esophageal Aden... Microsatellite ... | Nivolumab or Pe... Metformin Rosiglitazone | 18 Years - | University of Pittsburgh | |
| Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer | NCT03592407 | Esophageal Squa... Esophageal Aden... Gastroesophagea... | Epacadostat Laboratory Biom... Pembrolizumab Pharmacodynamic... | 18 Years - | City of Hope Medical Center | |
| The Microenvironment in Barrett's Esophagus | NCT03060642 | Barrett Esophag... Esophageal Aden... | Tethered capsul... Electronic nose... | 18 Years - | Columbia University | |
| A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | NCT06356311 | Gastroesophagea... | Sacituzumab tir... Trifluridine-Ti... Irinotecan Paclitaxel Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | NCT05568095 | Advanced Upper ... | Domvanalimab Zimberelimab Capecitabine Fluorouracil Leucovorin Oxaliplatin Nivolumab | 18 Years - | Arcus Biosciences, Inc. | |
| Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer | NCT02606396 | Esophageal Aden... | Cryotherapy Esophagogastrod... Endoscopic ultr... | 18 Years - | Hunter Holmes Mcguire Veteran Affairs Medical Center | |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | NCT05753748 | Barretts Esopha... Barrett Esophag... Esophageal Aden... | Endoscopic Erad... | 18 Years - 89 Years | University of Colorado, Denver | |
| Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus | NCT01298999 | Barrett's Esoph... | YF476 Placebo | 18 Years - | Columbia University | |
| Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | NCT05945823 | Locally Advance... Esophageal Aden... Esophageal Squa... Siewert Type 1 ... Pancreatic Canc... | Futibatinib Pembrolizumab Cisplatin 5-FU Oxaliplatin Leucovorin Levoleucovorin Irinotecan | 18 Years - | Taiho Oncology, Inc. | |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | NCT05954312 | Advanced Solid ... | VVD-130037 | 18 Years - | Vividion Therapeutics, Inc. | |
| Spray Cryotherapy for Esophageal Cancer (ICE-CANCER) | NCT01868139 | Esophageal Canc... | Liquid nitrogen... | 18 Years - | University of Maryland, Baltimore | |
| Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma | NCT01932580 | Gastric Adenoca... Esophageal Aden... | FLOT (5-fluorou... | 18 Years - | McGill University | |
| Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue | NCT00909350 | Barrett's Esoph... Esophageal Aden... | 18 Years - | Mayo Clinic | ||
| Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus | NCT01298999 | Barrett's Esoph... | YF476 Placebo | 18 Years - | Columbia University | |
| Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma | NCT01932580 | Gastric Adenoca... Esophageal Aden... | FLOT (5-fluorou... | 18 Years - | McGill University | |
| Confocal Endomicroscopy for Barrett's Esophagus | NCT00487695 | Barrett's Esoph... Esophageal Aden... | confocal laser ... standard endosc... | 18 Years - | Johns Hopkins University | |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | NCT04683939 | Solid Tumor Gastric Cancer Gastroesophagea... Esophageal Aden... Pancreatic Canc... Biliary Tract C... Cholangiocarcin... Metastatic Canc... | BNT141 Nab-paclitaxel Gemcitabine | 18 Years - | BioNTech SE | |
| Phase II Study of Irinotecan and Panitumumab | NCT00836277 | Esophageal Canc... | Panitumumab Irinotecan | 18 Years - | University of Pittsburgh | |
| Rapid Assessment of Esophageal Adenocarcinoma Risk Test | NCT03366012 | Barrett Esophag... Esophageal Aden... | Cytosponge | 50 Years - 75 Years | Columbia University | |
| Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC | NCT04295811 | Barrett Esophag... Esophageal Aden... Barretts Esopha... Barrett's Esoph... | EsoGuard (lab a... Esophagogastrod... | 50 Years - | PAVmed Inc. | |
| Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies | NCT03539822 | Gastric Cancer Esophageal Aden... Hepatocellular ... Colorectal Canc... | Cabozantinib Durvalumab Tremelimumab | 18 Years - | University of Pittsburgh | |
| Lucid Registry Study | NCT05965999 | Barrett Esophag... Esophageal Aden... Barretts Esopha... Barrett's Esoph... | EsoCheck | 12 Years - | PAVmed Inc. | |
| Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome | NCT02513784 | Esophageal Aden... Barrett's Esoph... Reflux Esophagi... | Chlorhexidine g... | 18 Years - | Columbia University | |
| Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material | NCT01970306 | Esophageal Aden... | MatriStem PSM | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer | NCT02128243 | Unresectable, L... Gastric Neoplas... Gastroesophagea... Esophageal Aden... Gastric Adenoca... Esophageal Neop... | S-1 de-escalati... Chemotherapy by... | 18 Years - | AIO-Studien-gGmbH | |
| Registry Platform Gastric/Esophageal Cancer (SAPHIR) | NCT04290806 | Esophageal Squa... Gastric Adenoca... Gastroesophagea... Esophageal Aden... | Routine care as... | 18 Years - | iOMEDICO AG | |
| Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue | NCT00909350 | Barrett's Esoph... Esophageal Aden... | 18 Years - | Mayo Clinic | ||
| Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma | NCT03015389 | Barrett Esophag... Esophageal Dysp... Esophageal Aden... | Diagnostic Test | 18 Years - | CDx Diagnostics | |
| Registry Platform Gastric/Esophageal Cancer (SAPHIR) | NCT04290806 | Esophageal Squa... Gastric Adenoca... Gastroesophagea... Esophageal Aden... | Routine care as... | 18 Years - | iOMEDICO AG | |
| Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma | NCT04089904 | Gastroesophagea... Gastric Adenoca... Esophageal Aden... | Pembrolizumab I... | 18 Years - | University of Chicago | |
| Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer | NCT01870791 | Esophageal Neop... Gastric Neoplas... | Omegaven | 18 Years - | University Hospitals, Leicester | |
| Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma | NCT04089904 | Gastroesophagea... Gastric Adenoca... Esophageal Aden... | Pembrolizumab I... | 18 Years - | University of Chicago | |
| Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery | NCT05713838 | Esophagus Adeno... | Durvalumab FLOT mFOLFOX-6 Radiotherapy | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer | NCT04929392 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Aden... Esophageal Squa... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... | Carboplatin Endoscopic Biop... External Beam R... Lenvatinib Mesy... Paclitaxel Pembrolizumab Resection | 18 Years - | City of Hope Medical Center | |
| Esophageal Protocol for Detection of Neoplasia in the Digestive Tract | NCT01391208 | Barrett Esophag... Esophageal Aden... | GI heptapeptide | 18 Years - | University of Michigan | |
| Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma | NCT03961945 | Barrett Esophag... Esophageal Aden... | Sponge Capsule | 18 Years - 90 Years | Mayo Clinic | |
| Esophageal Cytology With FISH in Detecting Esophageal Cancer | NCT02100189 | Dysphagia Dysplasia Esophageal Aden... Esophageal Squa... Esophagitis Gastroesophagea... High Grade Dysp... Weight Loss | Cytology Specim... Esophagogastrod... Laboratory Biom... | 18 Years - | OHSU Knight Cancer Institute | |
| Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas | NCT05745857 | Barrett's Esoph... Barrett Oesopha... Esophageal Aden... | Avastin Erbitux Fluorescence en... | 18 Years - | University Medical Center Groningen | |
| Public's Intended Uptake and Views on Organization of Esophageal Cancer Screening | NCT05690958 | Barrett Esophag... Barrett Adenoca... Esophageal Aden... | Survey | 45 Years - 75 Years | Radboud University Medical Center | |
| Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors | NCT04900818 | Solid Tumor Advanced Cancer Metastatic Canc... Gastric Cancer Gastroesophagea... Esophageal Aden... | TJ033721 | 18 Years - | I-Mab Biopharma US Limited | |
| Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma | NCT00964080 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | MBP-426/Leucovo... | 18 Years - | Mebiopharm Co., Ltd | |
| Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery | NCT03604991 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Aden... Gastroesophagea... | Biospecimen Col... Carboplatin Computed Tomogr... Ipilimumab Nivolumab Paclitaxel Positron Emissi... Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | NCT04060342 | Pancreatic Aden... Esophageal Aden... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Triple Negative... Castration-resi... Microsatellite ... Non-small Cell ... Small-cell Lung... Head and Neck S... Urothelial Carc... Renal Cell Carc... Hepatocellular ... | GB1275 nab-paclitaxel ... pembrolizumab | 18 Years - | Gossamer Bio Inc. | |
| Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans | NCT05591053 | Esophagus Cance... Esophageal Canc... Esophageal Neop... Esophageal Dise... Esophageal Aden... Esophageal Squa... Esophagus SCC Esophagus Tumor Esophagus Adeno... Esophagus Neopl... | ActivSight | 18 Years - | Activ Surgical | |
| ESD for the Treatment of Early Barrett's Neoplasia | NCT02583087 | Barrett Esophag... Esophageal Neop... | endoscopic subm... | 18 Years - 90 Years | Hôpital Cochin | |
| Public's Intended Uptake and Views on Organization of Esophageal Cancer Screening | NCT05690958 | Barrett Esophag... Barrett Adenoca... Esophageal Aden... | Survey | 45 Years - 75 Years | Radboud University Medical Center | |
| Confocal Endomicroscopy for Barrett's Esophagus | NCT00487695 | Barrett's Esoph... Esophageal Aden... | confocal laser ... standard endosc... | 18 Years - | Johns Hopkins University | |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | NCT05568095 | Advanced Upper ... | Domvanalimab Zimberelimab Capecitabine Fluorouracil Leucovorin Oxaliplatin Nivolumab | 18 Years - | Arcus Biosciences, Inc. | |
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | NCT04430738 | Colorectal Carc... Gastric Adenoca... GEJ Adenocarcin... Esophageal Aden... Cholangiocarcin... Gallbladder Car... | tucatinib trastuzumab oxaliplatin leucovorin fluorouracil capecitabine pembrolizumab | 18 Years - | Seagen Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
